Anti-NMDA receptor encephalitis pathophysiology: Difference between revisions
Created page with "__NOTOC__ {{Anti-NMDA receptor encephalitis}} {{CMG}} ==Overview== ==Pathophysiology== ==References== {{Reflist|2}} Category:Needs content Category:Rheumatology C..." |
|||
| Line 6: | Line 6: | ||
==Pathophysiology== | ==Pathophysiology== | ||
Anti-NMDA receptor encephalitis is predominantly caused by autoantibodies directed against the GluN1 component of the receptor. | |||
In the acute phase of brain diseases, B cells, plasma cells, CD4 T cells, and, less frequently, CD8 T cells have been detected. | |||
Crossing the blood-brain barrier enables systemically produced antibodies to crosslink NMDA receptors. This leads to their internalization and a severe disruption of synaptic plasticity and NMDA receptor network function. | |||
==References== | ==References== | ||
Revision as of 16:18, 10 December 2022
|
Anti-NMDA receptor encephalitis Microchapters |
|
Differentiating Anti-NMDA receptor encephalitis from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Anti-NMDA receptor encephalitis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis pathophysiology |
|
Directions to Hospitals Treating Anti-NMDA receptor encephalitis |
|
Risk calculators and risk factors for Anti-NMDA receptor encephalitis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pathophysiology
Anti-NMDA receptor encephalitis is predominantly caused by autoantibodies directed against the GluN1 component of the receptor.
In the acute phase of brain diseases, B cells, plasma cells, CD4 T cells, and, less frequently, CD8 T cells have been detected.
Crossing the blood-brain barrier enables systemically produced antibodies to crosslink NMDA receptors. This leads to their internalization and a severe disruption of synaptic plasticity and NMDA receptor network function.